InsiderTrades.com logo
Charles W. Newton net worth and biography
  • Phone
  • Email
  • Website

Charles Newton Biography and Net Worth

CFO of Lyell Immunopharma

Charles Newton has served as our Chief Financial Officer since February 2021. From November 2015 to February 2021, he served as Managing Director & Co-Head of Healthcare Investment Banking in the Americas at Bank of America. From September 2010 to November 2015, Mr. Newton served as Managing Director at Credit Suisse where his last position was Co-Head of Healthcare Investment Banking in the Americas. From June 1996 to September 2010, he served in the investment banking division at Morgan Stanley where his last position was Managing Director and Head of Western Region Healthcare Investment Banking. He currently serves as a member of the board of directors of Coherus BioSciences, Inc., a publicly traded company and Novavax, a publicly traded company. Previously, he served on the board of directors of 2seventy bio. Inc., a publicly traded company until its acquisition by Bristol Myers Squibb and Carmot Therapeutics, a private biopharmaceutical company until its acquisition by Roche. Mr. Newton received an MBA from The Tuck School at Dartmouth College and a B.S. in Finance from Miami University.

What is Charles W. Newton's net worth?

The estimated net worth of Charles W. Newton is at least $174.80 thousand as of August 11th, 2025. Mr. Newton owns 8,895 shares of Lyell Immunopharma stock worth more than $174,796 as of March 27th. This net worth estimate does not reflect any other assets that Mr. Newton may own. Learn More about Charles W. Newton's net worth.

How do I contact Charles W. Newton?

The corporate mailing address for Mr. Newton and other Lyell Immunopharma executives is , , . Lyell Immunopharma can also be reached via phone at 650-695-0677 and via email at [email protected]. Learn More on Charles W. Newton's contact information.

Has Charles W. Newton been buying or selling shares of Lyell Immunopharma?

Charles W. Newton has not been actively trading shares of Lyell Immunopharma during the last ninety days. Most recently, Charles W. Newton sold 136 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $10.34, for a transaction totalling $1,406.24. Following the completion of the sale, the chief financial officer now directly owns 8,759 shares of the company's stock, valued at $90,568.06. Learn More on Charles W. Newton's trading history.

Who are Lyell Immunopharma's active insiders?

Lyell Immunopharma's insider roster includes Otis Brawley (Director), Otis Brawley (Director), Stephen Hill (COO), Richard Klausner (Director), Richard Klausner (Founder & Board Chair), Gary Lee (Insider), Charles Newton (CFO), Charles Newton (CFO), Sumant Ramachandra (Director), Lynn Seely (President & Chief Executive Officer), and Lynn Seely (CEO). Learn More on Lyell Immunopharma's active insiders.

Are insiders buying or selling shares of Lyell Immunopharma?

In the last twelve months, Lyell Immunopharma insiders bought shares 1 times. They purchased a total of 1,782 shares worth more than $19,958.40. In the last twelve months, insiders at the sold shares 19 times. They sold a total of 13,710 shares worth more than $294,348.44. The most recent insider tranaction occured on February, 11th when CEO Lynn Seely sold 7,455 shares worth more than $174,372.45. Insiders at Lyell Immunopharma own 22.3% of the company. Learn More about insider trades at Lyell Immunopharma.

Information on this page was last updated on 2/11/2026.

Charles W. Newton Insider Trading History at Lyell Immunopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2025Sell136$10.34$1,406.248,759View SEC Filing Icon  
8/11/2025Sell131$10.53$1,379.438,895View SEC Filing Icon  
3/17/2025Buy10,000$11.20$112,000.0010,000View SEC Filing Icon  
See Full Table

Charles W. Newton Buying and Selling Activity at Lyell Immunopharma

This chart shows Charles W Newton's buying and selling at Lyell Immunopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lyell Immunopharma Company Overview

Lyell Immunopharma logo
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $19.36
Low: $18.30
High: $20.28

50 Day Range

MA: $23.32
Low: $19.12
High: $25.84

2 Week Range

Now: $19.36
Low: $7.65
High: $45.00

Volume

27,993 shs

Average Volume

103,089 shs

Market Capitalization

$451.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A